Mechanism of active components of "Notoginseng Radix et Rhizoma-Drynariae Rhizoma" in treatment of osteoporosis based on network pharmacology and in vitro cell experiment.
10.19540/j.cnki.cjcmm.20220926.501
- Author:
Wen-Jing YANG
1
;
Jian HUANG
2
;
Wei WANG
2
;
Li-Jun PENG
1
;
Jin-Yu LI
3
;
Wei-Feng ZHU
1
Author Information
1. Key Laboratory of Modern Chinese Materia Medica Preparation of Ministry of Education, Jiangxi University of Chinese Medicine Nanchang 330004, China.
2. Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
3. Key Laboratory of Modern Chinese Materia Medica Preparation of Ministry of Education, Jiangxi University of Chinese Medicine Nanchang 330004, China Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
- Publication Type:Journal Article
- Keywords:
Panax notoginseng saponins;
in vitro cell experiment;
mechanism;
molecular docking;
network pharmacology;
osteoporosis;
osteopractic total flavone
- MeSH:
Humans;
Molecular Docking Simulation;
Network Pharmacology;
Osteogenesis;
Phosphatidylinositol 3-Kinases;
Osteoporosis;
Databases, Genetic
- From:
China Journal of Chinese Materia Medica
2023;48(4):1087-1097
- CountryChina
- Language:Chinese
-
Abstract:
The present study aimed to explore the main active components and potential mechanisms of Panax notoginseng saponins(PNS) and osteopractic total flavone(OTF) in the treatment of osteoporosis(OP) through network pharmacology, molecular docking and in vitro cell experiments, which was expected to provide a theoretical basis for clinical applications. The blood-entering components of PNS and OTF were obtained from literature search and online database, and their potential targets were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP) and SwissTargetPrediction. The OP targets were obtained by means of searching Online Mendelian Inheritance in Man(OMIM) and GeneCards. The common targets of the drug and disease were screened by Venn. Cytoscape was used to construct a "drug-component-target-disease" network, and the core components were screened according to the node degree. The protein-protein interaction(PPI) network of the common targets was constructed by STRING and Cytoscape, and the core targets were screened according to the node degree. GO and KEGG enrichment analysis of potential therapeutic targets were carried out by R language. Molecular docking was used to determine the binding activity of some active components to key targets by AutoDock Vina. Finally, HIF-1 signaling pathway was selected for in vitro experimental verification according to the results of KEGG pathway analysis. Network pharmacology showed that there were 45 active components such as leachianone A, kurarinone, 20(R)-protopanaxatriol, 20(S)-protopanaxatriol, and kaempferol, and 103 therapeutic targets such as IL6, AKT1, TNF, VEGFA and MAPK3 involved. PI3K-AKT, HIF-1, TNF and other signaling pathways were enriched. Molecular docking revealed that the core components had good binding ability to the core targets. In vitro experiments found that PNS-OTF could up-regulate the mRNA expression levels of HIF-1α, VEGFA and Runx2, indicating that the mechanism of PNS-OTF in treating OP may be related to the activation of HIF-1 signaling pathway, and thus PNS-OTF played a role in promoting angiogenesis and osteogenic differentiation. In conclusion, this study predicted the core targets and pathways of PNS-OTF in treating OP based on network pharmacology and carried out in vitro experimental verification, which reflected the characteristics of multi-component, multi-target and multi-pathway synergy of PNS-OTF, and provided new ideas for the future clinical treatment of OP.
